How to Spot Safe Cannabis Products for Cancer Care
Nurses need to know where patients are getting their cannabis products and should look out for a few red flags.
Related Articles
Optimizing Management of Chronic GVHD: The Care Team’s Role in Symptom Management and Patient Care
Experts explore chronic graft-versus-host disease (cGVHD), discussing its symptoms, patient impact, treatment approaches including emerging therapies like axatilimab, and strategies for symptom management and patient…
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers
Adding E-602 to cemiplimab demonstrated anti-tumor effects in patients PD-L1–resistant solid cancers.
Tafasitamab Shows Real-World Efficacy in Relapsed/Refractory DLBCL
Treatment with tafasitamab for relapsed/refractory DLBCL in the United States was supported by data from a retrospective analysis.
CRB-701 Receives FDA Fast Track Designation for Relapsed/Refractory Cervical Cancer
The FDA granted fast track designation to CRB-701 for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.
Optimizing Management of Chronic GVHD: The Care Team’s Role in Symptom Management and Patient Care
Experts explore chronic graft-versus-host disease (cGVHD), discussing its symptoms, patient impact, treatment approaches including emerging therapies like axatilimab, and strategies for symptom management and patient…
NCCN Updates Guidelines for Preferred Frontline Regimen for Advanced Nasopharyngeal Carcinoma
The NCCN Guidelines Version 1.2025 for Cancer of the Nasopharynx listed toripalimab plus chemotherapy as the standalone preferred regimen in the frontline treatment of patients…
Addition of Cadonilimab Improves Survival in Advanced Cervical Cancer
Cadonilimab plus platinum-based chemotherapy improved progression-free and overall survival in advanced cervical cancer compared to placebo, showing significant clinical benefits.
FDA Approves Durvalumab in Limited-Stage Small Cell Lung Cancer
The agency granted approval to durvalumab for the treatment of a subset of patients with limited-stage small cell lung cancer.
FDA Approves First and Only Systemic Therapy for NRG1+ Lung, Pancreatic Cancers
Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or pancreatic adenocarcinoma (PDAC) harboring an NRG1 gene…
LBS-007 Receives FDA Fast Track Designation for Acute Myeloid Leukemia
The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.